#Reprise iconiq growthsawersventurebeat trial
#Reprise iconiq growthsawersventurebeat series

#Reprise iconiq growthsawersventurebeat trial

For example, Care Access partnered with Eli Lilly to safely take a COVID trial to the residents of a nursing home. The platform drives tremendous impact as evidenced by the nearly 4,000 research sites globally using the product. Reify Health is working with half of the global top 20 biopharma sponsors in the world (and seven of the top ten), including AstraZeneca, Amgen, and Eli Lilly and Company. Together, StudyTeam and Care Access are in our opinion truly revolutionizing the way clinical trials are conceptualized and conducted: thanks to these businesses, trials can not only be run faster, but also be run anywhere. Instead of requiring patients to travel to specific clinical trial sites, Care Access is bringing the trials to the patients, wherever they may be. But what Reify Health does “goes beyond decentralized trials,” said Michael Lin, who explained “we need to have a global healthcare system proactively reaching out to patients everywhere and mobilizing the resources necessary to bring trials to them.” This is especially valuable in communities that may previously have been inaccessible or underrepresented due to limited infrastructure. Care Access provides a set of comprehensive trial delivery services that also helps create “plug and play” decentralized clinical trials. By providing these sponsors visibility into patient enrollment happening at the research site, StudyTeam communicates process bottlenecks and enables timely intervention to reduce trial delays and large overhead. StudyTeam helps connect biopharma sponsors to clinical sites to accelerate patient enrollment and preparation for trial delivery. Through StudyTeam and Care Access, the company provides what we believe is best-in-class clinical optimization software, with a focus on effective enrollment, and transformative clinical trial infrastructure that delivers research directly to more healthcare providers, communities, and patients wherever they are. We believe Reify Health is paving the way to faster, predictable, and more accessible clinical trials. In addition, the need for further diversity within patient populations in clinical trials is more acute than ever, which makes process visibility and control even more important. In a recent interview, Ralph Passarella said, “sponsors have looked at solutions to make clinical research more accessible to patients and possible for more professionals to participate.” Inefficient patient enrollment creates several far-ranging consequences in the research and development lifecycle, leading to patients with life-threatening and extremely rare conditions being forced to wait for potentially life-saving therapeutics for years. Most biopharma sponsors and clinical research sites find patient enrollment to be one of the biggest challenges to running a successful trial. We at ICONIQ Growth are excited to partner with visionaries like Ralph, Michael and their team at Reify Health as they execute on a bold mission. Having seen family members go through clinical trials, Ralph and Michael know firsthand how critical clinical research can be to patients with rare medical conditions seeking hope in the form of experimental treatments. For Ralph and Michael, this challenge is not just another business problem, but one that is deeply personal. The duo started Reify Health in 2012 to accelerate clinical trials and bring life-saving therapies to market faster. The two met at the Johns Hopkins University School of Medicine and instantly connected on the need to bring transparency to an ecosystem that has historically worked in arcane silos. “This funding will accelerate getting our product into the hands of customers that need it.When our team at ICONIQ Growth first met Ralph Passarella and Michael Lin, we were immediately struck by their ambitious vision for a very different future of clinical trials - one we believe is radically more accessible, scalable, and efficient. “Sales and marketing teams need to use their product to spur growth, but relying on engineering teams and slow demo environments kills their momentum,” Reprise co-CEO Bryan Stevenson said. With another $62 million in the bank, from lead investor Iconiq Growth, Bain Capital Ventures, Accomplice VC, Glasswing Ventures, and a slew of angel investors including The Daily Show’s Trevor Noah, the company is now well-financed to “expand its customer base and increase the depth of its enterprise platform,” according to a press release.

#Reprise iconiq growthsawersventurebeat series

Prior to now, Reprise had raised around $20 million since its inception last year, the bulk of which arrived via its series A round just nine months ago. Reprise also offers an API that allows companies to pull data from its platform and push into a data warehouse or lake and combine with data from other platforms to get a fuller picture of how customers perceive a product, or simply keep marketing or sales data records up-to-date.